Login to Your Account

Oxyrane Brings in $26.5M to Fund Pompe's Drug R&D

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 23, 2011
LONDON – Oxyrane Ltd. has raised $26.5 million in a fourth private round as it prepares to move its first enzyme replacement therapy into clinical development for the treatment of Pompe's disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription